The acyclic purine nucleoside analogue 9-(2-phosphonomethoxyethyl)adenine [PMEA; formerly referred to as 9-(2-phosphonylmethoxyethyl)adenineJ is a potent and selective inhibitor of human immunodeficiency virus replication in vitro and of Moloney murine sarcoma virus-induced tumor formation in mice. In the latter system PMEA has stronger antiretroviral potency and selectivity than 3'-azido-3'-thymidine (AZT). We have now investigated the effect of the drug in cats infected with the feline immunodefciency virus (FlY). In vitro, PMEA was found to efficiently block FIV replication in feline thymocytes (50% effective dose, 0.6 ,uM).
Acquired immunodeficiency syndrome (AIDS) is caused by human immunodeficiency virus (HIV), a retrovirus of the lentivirinae subfamily (1, 2) . So far, only 3'-azido-3'-deoxythymidine (AZT; Zidovudine) has unambiguously demonstrated clinical benefit in the treatment of AIDS patients (3) (4) (5) . Despite toxic side effects like megaloblastic anemia and evidence that AZT resistance is developing among strains of HIV-1, the drug is valuable since it has the capacity of extending the lives of AIDS patients (6) . The development of AZT-resistant strains of HIV-1 is troubling; however, cross-resistance has been observed to only one other nucleoside, 3'-azido-2',3'-dideoxyuridine, which is closely related to AZT. Therefore, other efficacious antiretroviral drugs have to be developed; resistance can then be avoided or mitigated by alternating drug use. Many compounds that possess the same mode of action as AZT have been evaluated in vitro, and some compounds reported to be potent and selective inhibitors of HIV replication in vitro have passed phase II clinical trials.
We have found (7) that the acyclic adenosine derivative 9-(2-phosphonomethoxyethyl)adenine [PMEA; formerly referred to as 9-(2-phosphonylmethoxyethyl)adenine] inhibits HIV-induced cytopathogenicity in human T-lymphocyte MT-4, H9, and ATH8 cells. The effective concentration (1.6-2 ,uAM) ofthe drug is far below the cytotoxic threshold for the host cells (40-67 ,uM) (7) . PMEA also inhibits simian immunodeficiency virus replication in MT-4 cells, simian AIDS-related virus-induced giant cell formation in Raji cells, and transformation of murine C3H embryo fibroblasts by Moloney murine sarcoma virus (7) (8) (9) . Over a wide range of doses (1-50 mg/kg per day) PMEA caused a 90-10%o protection of mice against Moloney murine sarcoma virusinduced tumor formation and associated mortality, Friend leukemia virus-induced splenomegaly in BALB/c mice, and LP-BM5-induced immunosuppression and mortality in mice (8, (10) (11) (12) .
Until recently, a major problem in evaluating antiretroviral compounds with proven activity against HIV in vitro was the lack of a natural immunosuppressive lentivirus infection model in animals. Pedersen et al. (13) have discovered a lentivirus, feline immunodeficiency virus (FIV) , that causes a condition in cats that is very similar to AIDS in humans. FIV infection meets criteria of an animal model for AIDS; FIV is genetically similar to HIV (14-16) and causes a disease with a similar pathogenesis (13, 17) . The reverse transcriptase (RT) of FIV is similar to that of HIV-1 in its sensitivity to several antiretroviral compounds, including AZT and phosphonoacetate (18) . FIV replicates preferentially in T lymphocytes, macrophages, and neural cells (refs. 19-21; H.E., unpublished data). In cats the infection is characterized by an initial asymptomatic phase of several months or even years during which virus can be demonstrated (19) . Subsequently, clinical signs may develop consisting of anorexia, weight loss, stomatitis, gingivitis, rhinitis, diarrhea, pustular dermatitis, anemia, and generalized lymphadenopathy (22, 23) . Ultimately, the infected animals may die of opportunistic infections.
Feline leukemia virus infection has been used as a model for antiretroviral chemotherapy studies in vitro and in vivo (24, 25) ; however, the use of a lentivirus, rather than of an oncovirus, would be preferred as an animal model for AIDS; FIV fulfills this requirement.
In the present study we report that the anti-HIV drug PMEA interferes with the replication of FIV in vitro and in vivo; furthermore, PMEA treatment was found to cause clinical improvement of diseased cats in the field.
MATERIALS AND METHODS
Virus and Cells. The virus strains FIV-48 and FIV-113 were isolated from peripheral blood mononuclear cells of seropositive field cats with severe stomatitis and gingivitis. Virus stocks were prepared by the cocultivation method using feline thymocytes collected from specific pathogen-free cats $To whom reprint requests should be addressed.
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(Harlan, Zeist, The Netherlands) stimulated with concanavalin A at 5 ug/ml and cultured in RPMI 1640 medium containing 10% (vol/vol) fetal calf serum supplemented with recombinant interleukin 2 (at 100 international units/ml). Virus yields were determined by assaying the RT activity in the culture supernatants. Crandell feline kidney cells (CRFK) persistently infected with the isolate FIV-113 were used for large-scale antigen production. The procedures to concentrate and purify virus have been described (26) .
Antibody Assays. FIV-specific antibodies were assayed using an indirect immunofluorescence assay (IFA) on FIVinfected CRFK cells and a standard laboratory ELISA based upon sucrose-gradient purified virus as antigen source. The standard ELISA was as sensitive as the commercial FIV ELISA (Idexx, Portland, ME).
Inhibitory Effect of PMEA on FIV Replication in Feline Thymocytes. The anti-FIV activity of AZT and PMEA was determined in feline thymocytes. Mitogen-stimulated thymocytes were seeded at 1 x 106 cells per ml into 1.6-cm2 wells of a 24-well tissue culture plate containing various concentrations of the test compounds. After a 1-hr incubation at 37°C, cells were infected with FIV (equivalent to 6 x 105 cpm of RT activity) for 60 min. Then the medium was replaced by 1 ml of fresh culture medium containing various concentrations of the compounds to be tested. After 4 and 6 days of culture, the RT activity in the culture supernatants and the number of viable cells (trypan blue exclusion) were determined in parallel for both mock-and FIV-infected cells. The 50% effective dose (ED50) was defined as the concentration of compound that reduced the RT activity by 50%, whereas the 50% cytotoxic dose (CD50) corresponded to the concentration of compound that reduced the number of viable mock-infected cells by 50%. Therapeutic Effect of PMEA on FIV Infection. The therapeutic effect of PMEA was evaluated in experimentally infected asymptomatic cats and in seropositive diseased field cats. In experimentally infected asymptomatic cats treated with PMEA at a dose of 5 mg/kg per day, the release of virus from peripheral blood lymphocytes was again delayed whereas antibody titers were not affected at all doses used (2, 5, or 20 mg/kg per day) (data not shown). When compared to the untreated animals, a 50-to 230-fold reduction of RT activity was observed. The RT activity had been calculated per 1 x 105 viable peripheral blood lymphocytes isolated at day 21 after onset of the therapy; the cells had been stimulated with concanavalin A and maintained on interleukin 2 for 13 days.
The drug had a pronounced effect on the opportunistic infections accompanying FIV persistence in field cats when administered at a dose of 5 mg/kg per day. Five out of six treated cats recovered from a variety of severe symptoms (stomatitis, gingivitis, and diarrhea) or showed general clinical improvement (Table 3) . Cat 5 with a history of stomatitis ( Fig. 2A ) that had not responded to prolonged corticosteroid treatment completely recovered when treated with PMEA (Fig. 2B) . Recurrence of the symptoms was noted 2 months after the first therapy had been discontinued. The cat recovered from stomatitis and showed general clinical improvement when the same regimen (3 weeks) of PMEA treatment was applied. Symptoms reappeared 8 months after the sec- ond therapy had been discontinued and the cat again responded well to a third PMEA treatment (3 weeks).
Six weeks after the therapy had been discontinued cat 1 also showed recurrence of the symptoms (Table 3 ). The cat responded well to a second PMEA treatment. Four out offive cats are still healthy 9 months after termination of therapy (Table 3) . DISCUSSION FIV infection of cats meets many criteria of an animal model for HIV infection of man; as demonstrated in this report, it can be used to study the efficacy ofantiretroviral agents in the treatment of immunosuppressive lentivirus infections in vivo.
In the Moloney murine sarcoma virus infection model, PMEA has a stronger in vivo antiretrovirus potency and selectivity than several other compounds including AZT (8, 9) . Here, we demonstrate that PMEA has proved at least as efficacious as AZT in suppressing FIV infection in vitro (18) ; it also had a marked effect on FIV-associated symptoms in cats. Adverse reactions (e.g., megaloblastic anemia), described after AZT treatment ofhumans (6), were observed for PMEA only at high doses (20 mg/kg per day). The question whether PMEA treatment leads to drug-resistant strains of FIV has still to be addressed; in our patients, the drug still had a pronounced effect after the second recurrence of symptoms in cat 5.
PMEA also inhibits herpes simplex virus infections in vivo (12, 27) . Feline caliciviruses and feline herpesvirus are associated with oropharyngeal disease in cats (28) . The oropharyngeal symptoms ofchronic infections are observed in about 50% of FIV cats in North America (19) and Japan (29) . Feline herpesvirus occurs in between 25% and 80%o of healthy cats as a latent infection (30) and its activation by a immunosuppression has been established (31) . It would therefore appear that the clinical improvement seen after PMEA treatment has been due to a combined effect of inhibiting FIV replication with its immunosuppressing consequences as well as feline herpesvirus. The dual antiviral activity of PMEA may broaden its therapeutic usefulness in controlling the opportunistic infections; this has been seen in FIV-infected field cats and may prove valuable in the human AIDS pathogenesis.
Previous studies have shown that radiolabeled PMEA, besides accumulating in the liver and kidneys, crosses the blood-brain barrier (8, 27) . This latter property is important in view of the propensity of lentiviruses, in particular HIV and FIV, to infect and damage the central nervous system.
In conclusion, we report an immunosuppressive natural lentivirus infection that can be influenced by chemotherapy. The compound PMEA deserves further investigation as a drug for treatment of HIV infections in humans; FIV infection in cats can be considered as a useful and readily available model for in vivo screening of antilentivirus compounds.
